Format

Send to

Choose Destination
Drugs Today (Barc). 2012 Sep;48(9):587-93. doi: 10.1358/dot.2012.48.9.1835160.

Lucinactant for the treatment of respiratory distress syndrome in neonates.

Author information

1
Department of Anesthesiology, University of Colorado Denver, Aurora, Colorado 80045, USA.

Abstract

Respiratory distress syndrome (RDS) is a leading cause of morbidity and mortality in premature neonates. This syndrome is caused by a lack of endogenous surfactant production in the lungs. Surfactant replacement was established as a safe and effective treatment in the 1990s and has become the standard of care for these infants. Surfactant products are either protein-free synthetic phospholipid compounds or animal-derived lung preparations. Currently, about 90,000 infants a year receive treatment with one of the commercially available animal-derived surfactants. Lucinactant (Surfaxin®) is a new synthetic surfactant with a pulmonary surfactant-associated protein B mimic that recently received FDA approval. The clinical trials that have been performed, although underpowered, may indicate that lucinactant is superior to phospholipid synthetic surfactant preparations and at least as effective as animal-derived surfactants in reducing morbidity and mortality from RDS. This review summarizes the current clinical knowledge about lucinactant.

PMID:
23032799
DOI:
10.1358/dot.2012.48.9.1835160
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Clarivate Analytics
Loading ...
Support Center